• First patient enrolled and dosed in new pancreatic cancer trial
• Trial investigating combination of Amplia's FAK inhibitor narmafotinib with FOLFIRINOX chemotherapy
• Trial being conducted at sites in Australia and the US

Amplia Therapeutics Limited (ASX: ATX) has announced that the first patient has been enrolled and has begun dosing in the company's new pancreatic cancer trial. The trial is exploring the combination of Amplia's best-in-class FAK inhibitor narmafotinib with the chemotherapy FOLFIRINOX in newly diagnosed advanced pancreatic cancer patients. The trial is being conducted at two (2) sites in Australia that are already open and recruiting patients, and four (4) sites in the US that will shortly be open once final site approvals are obtained. The first stage of this trial will explore the safety, tolerability and pharmacokinetics of increasing daily doses of narmafotinib when combined with FOLFIRINOX given on its conventional two (2) week cycle. The dose-escalation is anticipated to be completed in Q1 2026. Narmafotinib (AMP945) is Amplia's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently being investigated in the ACCENT clinical trial where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer, achieving a response rate of 31%, superior to chemotherapy alone.